Head and Neck Cancers Promote an Inflammatory Transcriptome through Coactivation of Classic and Alternative NF-κB Pathways
Authors:
- 1 November 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 7 (11) , 1760-1774
Abstract
Head and neck squamous cell carcinomas (HNSCC) promote inflammation in the tumor microenvironment through aberrant NF-κB activation, but the genomic alterations and pathway networks that modulate NF-κB signaling have not been fully dissected. Here, we analyzed genome and transcriptome alterations of 279 HNSCC specimens from The Cancer Genome Atlas (TCGA) cohort and identified 61 genes involved in NF-κB and inflammatory pathways. The top 30 altered genes were distributed across 96% of HNSCC samples, and their expression was often correlated with genomic copy-number alterations (CNA). Ten of the amplified genes were associated with human papilloma virus (HPV) status. We sequenced 15 HPV− and 11 HPV+ human HNSCC cell lines, and three oral mucosa keratinocyte lines, and supervised clustering revealed that 28 of 61 genes exhibit altered expression patterns concordant with HNSCC tissues and distinct signatures related to their HPV status. RNAi screening using an NF-κB reporter line identified 16 genes that are induced by TNFα or Lymphotoxin-β (LTβ) and implicated in the classic and/or alternative NF-κB pathways. Knockdown of TNFR, LTBR, or selected downstream signaling components established cross-talk between the classic and alternative NF-κB pathways. TNFα and LTβ induced differential gene expression involving the NF-κB, IFNγ, and STAT pathways, inflammatory cytokines, and metastasis-related genes. Improved survival was observed in HNSCC patients with elevated gene expression in T-cell activation, immune checkpoints, and IFNγ and STAT pathways. These gene signatures of NF-κB activation, which modulate inflammation and responses to the immune therapy, could serve as potential biomarkers in future clinical trials.Keywords
All Related Versions
Funding Information
- NIDCD (ZIA-DC-000016, 73, and 74)
- NCI NIH (HHSN261200800001E)
This publication has 54 references indexed in Scilit:
- Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV− and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation TherapyClinical Cancer Research, 2019
- Lymphotoxin‐β receptor‐NIK signaling induces alternative RELB/NF‐κB2 activation to promote metastatic gene expression and cell migration in head and neck cancerMolecular Carcinogenesis, 2018
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint BlockadeCell Reports, 2017
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint BlockadeCell, 2016
- The prognostic landscape of genes and infiltrating immune cells across human cancersNature Medicine, 2015
- Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancerOncogene, 2013
- HPV-associated head and neck cancer: a virus-related cancer epidemicThe Lancet Oncology, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Inhibitor-κB Kinase in Tumor Promotion and Suppression During Progression of Squamous Cell CarcinomaClinical Cancer Research, 2007
- PRISM: protein interactions by structural matchingNucleic Acids Research, 2005